TL;DR
Mutations in the KDM6A gene act as a "double-edged sword" in bladder cancer: they significantly improve a patient's response to immunotherapy (ICT) but simultaneously drive resistance to standard cisplatin-based chemotherapy. This happens because the loss of KDM6A triggers a two-pronged shift—breaking the cell's DNA repair machinery and "starving" the tumor’s immunosuppressive environment of lactate.
Abstract
Mutations in epigenetic regulators are frequent in bladder cancer, yet their impact on therapeutic efficacy remains poorly defined. This study investigates KDM6A, a histone demethylase frequently mutated in this disease. Retrospective clinical analyses reveal that KDM6A mutations correlate with improved overall survival (OS) in patients receiving immune checkpoint therapy (ICT), but are associated with lower OS in those undergoing cisplatin-based chemotherapy. Mechanistically, KDM6A loss downregulates DNA repair pathways, increasing genomic instability and ICT sensitivity while inducing cisplatin resistance. Additionally, KDM6A deficiency reduces glycolysis and lactate production, impairing histone lactylation in Regulatory T cells (Tregs) and diminishing their immunosuppressive function. These findings highlight KDM6A mutation status as a potential biomarker for personalizing bladder cancer treatment.
Introduction
Bladder cancer is a leading cause of cancer-related mortality. While traditional cisplatin-based chemotherapy and newer immune checkpoint therapies (ICT) are available, clinicians lack robust biomarkers to predict which patients will benefit most from each approach. KDM6A, an epigenetic regulator, is mutated in approximately 26% of bladder cancer cases. This study explores the role of KDM6A in modulating therapeutic responses, providing a mechanistic basis for patient stratification.
Methods
The researchers employed a multi-faceted approach combining clinical data and preclinical models:
- Clinical Correlation: Retrospective analysis of major patient cohorts, including IMVigor210, TCGA, MSK_2018, and HCRN, to link KDM6A mutations with survival outcomes.
- Preclinical Modeling: CRISPR-Cas9 was used to delete Kdm6a in murine bladder cancer cell lines (MB49) to observe therapeutic responses in vivo.
- Mechanistic Profiling: RNA-seq, ChIP-seq, and mass spectrometry (LC-MS/MS) were used to analyze gene expression, epigenetic marks (specifically histone lactylation), and metabolic shifts.
- Immune Analysis: Mass cytometry (CyTOF) characterized the tumor microenvironment (TME) and immune cell populations, focusing on the ratio of cytotoxic T cells to Tregs.
Key Insights
Genomic Instability and Therapy Response
Loss of KDM6A leads to the downregulation of DNA mismatch repair (MMR) and double-strand break repair (DSBR) genes. This results in increased genomic instability, making the tumor more immunogenic and responsive to ICT. However, because cisplatin efficacy depends on a functional MMR system to trigger apoptosis in response to DNA damage, KDM6A-deficient cells exhibit reduced sensitivity to chemotherapy.
Metabolic and Epigenetic Regulation of Tregs
KDM6A deficiency suppresses glycolytic activity, leading to reduced intratumoral lactate levels. This metabolic shift prevents histone lactylation (H3K9la and H3K18la) in Tregs, which is necessary for the expression of key immunosuppressive genes like Foxp3, Tgfb, and Pdcd1. Consequently, the loss of KDM6A reduces the expansion of PD-1<sup>hi</sup> Tregs, improving the ratio of cytotoxic T cells to Tregs and enhancing the anti-tumor response.
Results
Clinical data demonstrated a clear divergence in survival based on KDM6A status: mutant patients fared significantly better on ICT but worse on chemotherapy. Preclinical models confirmed that Kdm6a loss improves response to anti-PD-1 therapy while lowering sensitivity to cisplatin.
Conclusion
This study identifies KDM6A as a critical determinant of therapeutic response in bladder cancer. By acting as a biomarker for both ICT sensitivity and chemotherapy resistance, KDM6A mutation status can guide the development of personalized treatment algorithms. Future research may investigate the potential of PARP inhibitors to target the DNA repair vulnerabilities identified in KDM6A-deficient tumors.
Summary updated